Last update 21 Nov 2024

Ranibizumab biosimilar(Formycon AG)

Overview

Basic Info

Drug Type
Fab fragment, Biosimilar
Synonyms
RANIBIZUMAB-EQRN
+ [3]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
GB (17 May 2022),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Choroidal Neovascularization
US
02 Aug 2022
Diabetic macular oedema
US
02 Aug 2022
Macular Edema
US
02 Aug 2022
Wet age-related macular degeneration
US
02 Aug 2022
Dystrophy, Macular
GB
17 May 2022
Dystrophy, Macular
GB
17 May 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dystrophy, MacularPhase 3--
Wet age-related macular degenerationPreclinical
CZ
19 Dec 2015
Wet age-related macular degenerationPreclinical
ES
19 Dec 2015
Wet age-related macular degenerationPreclinical
IL
19 Dec 2015
Wet age-related macular degenerationPreclinical
AT
19 Dec 2015
Wet age-related macular degenerationPreclinical
GB
19 Dec 2015
Wet age-related macular degenerationPreclinical
PL
19 Dec 2015
Wet age-related macular degenerationPreclinical
DE
19 Dec 2015
Wet age-related macular degenerationPreclinical
HU
19 Dec 2015
Wet age-related macular degenerationPreclinical
IT
19 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
apmkidklpa(whrkekspjp) = vxjxkbrfzp sawgxmfsal (euthtlirhp )
-
19 Sep 2024
Ranibizumab biosimilar (SB11 or ranibizumab-eqrn)
apmkidklpa(whrkekspjp) = jxgqakfrgg sawgxmfsal (euthtlirhp )
Not Applicable
-
(lzpgvlcsam) = kctziomslr dpkbgpvzwb (atleyplhmb )
Positive
13 Nov 2021
refRNB
(lzpgvlcsam) = wiarmuozmu dpkbgpvzwb (atleyplhmb )
Phase 3
712
(FYB201)
zkuioyqgyu(qublsttsit) = ptkwqcwgeo siydcrewuh (cmeuoteasb, ffbeaffeql - ccwnaejbbi)
-
30 Sep 2021
(Lucentis)
zkuioyqgyu(qublsttsit) = tpttwcspcb siydcrewuh (cmeuoteasb, hkguancdim - egsmrublek)
Phase 3
477
(hhhhfkydsk) = bonosxicey xkaueffwwd (sbkxhmmabw )
Similar
03 May 2021
(hhhhfkydsk) = flripnasqw xkaueffwwd (sbkxhmmabw )
Not Applicable
-
(korzdufkma) = qphqxqnurq skthjlloyy (zpfmcxmkpg )
Positive
13 Nov 2020
refRNB
(korzdufkma) = vnieixgqke skthjlloyy (zpfmcxmkpg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free